Harbour Investments Inc. Grows Holdings in Axon Enterprise, Inc $AXON

Harbour Investments Inc. increased its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 24.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 558 shares of the biotechnology company’s stock after buying an additional 110 shares during the period. Harbour Investments Inc.’s holdings in Axon Enterprise were worth $462,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXON. Jennison Associates LLC increased its stake in Axon Enterprise by 23,203.7% during the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after buying an additional 611,418 shares during the period. Nuveen LLC purchased a new stake in Axon Enterprise during the 1st quarter worth $264,796,000. McElhenny Sheffield Capital Management LLC purchased a new stake in Axon Enterprise during the 2nd quarter worth $255,833,000. Westfield Capital Management Co. LP increased its stake in Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after buying an additional 212,931 shares during the period. Finally, Vanguard Group Inc. increased its stake in Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after buying an additional 185,571 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Up 1.9%

NASDAQ AXON opened at $683.13 on Tuesday. Axon Enterprise, Inc has a one year low of $422.38 and a one year high of $885.91. The company has a 50-day simple moving average of $736.73 and a 200-day simple moving average of $720.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The firm has a market capitalization of $53.63 billion, a PE ratio of 168.67, a price-to-earnings-growth ratio of 26.04 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same period in the previous year, the business posted $1.20 EPS. The company’s quarterly revenue was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AXON. Piper Sandler began coverage on shares of Axon Enterprise in a report on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 price objective for the company. Morgan Stanley set a $885.00 price objective on shares of Axon Enterprise and gave the stock an “overweight” rating in a report on Friday, July 11th. JMP Securities reissued a “market outperform” rating and set a $825.00 price objective on shares of Axon Enterprise in a report on Monday, September 29th. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Wolfe Research began coverage on shares of Axon Enterprise in a report on Monday, July 7th. They set an “outperform” rating for the company. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $841.64.

Insiders Place Their Bets

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 7,891 shares of the business’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $750.10, for a total transaction of $5,919,039.10. Following the completion of the transaction, the insider directly owned 144,538 shares of the company’s stock, valued at $108,417,953.80. The trade was a 5.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the transaction, the president directly owned 238,379 shares of the company’s stock, valued at $177,892,712.54. The trade was a 6.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 59,932 shares of company stock worth $45,115,616. Corporate insiders own 5.70% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.